Market news

MD posts 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, aided by stronger reimbursement and acquisitions.

Pediatrix Medical Group (MD) has drawn fresh attention after trading around a recent close of US$25.93. Investors are weighing this level against the company’s longer term return record and its current healthcare services footprint. Recent trading has been choppy for Pediatrix Medical Group, with a 1-day share price return of 1.73% offsetting some of the pressure from a 7-day share price return that slipped 3.64%. At the same time, the year-to-date share price return of 21.79% and a 1-year...

On August 4, Pediatrix Medical Group (NYSE:MD) reported second-quarter results that look strong on the surface. Adjusted earnings per share jumped to $0.63 from $0.53, and net revenue grew to $487.8 million. But look past the headline numbers, and the growth is coming largely from pricing and a shrinking share count, not from more patients […]

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Looking back on healthcare providers & services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Pediatrix Medical Group (NYSE:MD) and its peers.

Pediatrix Medical Group (MD) has an average rating of hold and mean price target of $26.33, accordin

MD's stronger cash collections, favorable payer mix, acquisitions and telehybrid care support its growth prospects.

Pediatrix Medical Group’s second quarter was marked by revenue growth exceeding Wall Street’s expectations, but the market responded negatively, reflecting concerns about profitability and underlying operational trends. Management attributed the top-line gains to improved revenue cycle management collections, a favorable payer mix, and rising patient acuity, while acknowledging a modest decline in same-unit patient volumes, particularly in neonatology. CEO Mark Ordan noted, “Same unit revenue wa

Detailed price information for Pediatrix Medical Group Inc (MD-N) from The Globe and Mail including charting and trades.

MD posts a Q2 earnings beat as stronger cash collections and a favorable payor mix lift results despite lower volumes.

Pediatrix Medical Group (MD) has an average rating of overweight and mean price target of $24.50, ac

Pediatrix Medical Group (NYSE:MD) reported second-quarter 2026 adjusted EBITDA of $76 million and reaffirmed its full-year adjusted EBITDA outlook of $280 million to $300 million, as stronger revenue-cycle-management collections, payer mix and patient acuity offset lower patient-service volumes. Ch

Moby summary of Pediatrix Medical Group, Inc.'s Q2 2026 earnings call

Pediatrix Medical Group Inc (MD) reaffirms full-year guidance as pricing gains offset softer neonatology volumes.

Detailed price information for Pediatrix Medical Group Inc (MD-N) from The Globe and Mail including charting and trades.

Pediatrix Medical Group (NYSE:MD) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of +10.53% and +2.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 4% year on year to $487.8 million. Its non-GAAP profit of $0.63 per share was 6.6% above analysts’ consensus estimates.

Pediatrix Medical Group: Q2 Earnings Snapshot

Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) will be reporting earnings this Tuesday before market open. Here’s what to look for.

Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) will be reporting earnings this Tuesday before market open. Here’s what to look for.

Detailed price information for Pediatrix Medical Group Inc (MD-N) from The Globe and Mail including charting and trades.

Pediatrix Medical Group (MD) drew fresh investor attention after updating second quarter business trends, highlighting a stable payor mix and reaffirming its full year 2026 Adjusted EBITDA outlook of $280 million to $300 million. See our latest analysis for Pediatrix Medical Group. Pediatrix Medical Group’s recent update on stable business trends comes after a strong run, with a year to date share price return of 23.72% and a 1 year total shareholder return of 105.14%. The latest 1 day move...

Pediatrix Medical Group (MD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Pediatrix Medical Group recently reported that its second-quarter 2026 payor mix and other net revenue-related trends remained stable and in line with recent history and internal expectations, while also reaffirming its full-year 2026 Adjusted EBITDA outlook of US$280 million to US$300 million. This confirmation of steady reimbursement patterns and earnings guidance, at a time when many healthcare peers report pressure on payor mix and utilization, highlights Pediatrix’s relatively resilient...

FORT LAUDERDALE, Fla., July 15, 2026--Pediatrix Medical Group, Inc. (NYSE: MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today provided an update on its second quarter 2026 business trends.

Detailed price information for Pediatrix Medical Group Inc (MD-N) from The Globe and Mail including charting and trades.